Lung cancer trial tests double immunotherapy punch for Hard-to-Treat patients

NCT ID NCT06364917

Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 23, 2026 · Updated 27 times

Summary

This study is for people with advanced non-small cell lung cancer that does not have the PD-L1 protein, making it harder to treat. Researchers want to see if using two different immunotherapy drugs together with chemotherapy works better than just one immunotherapy drug with chemo. The trial will track changes in cancer DNA in the blood to measure how well the treatment is working. About 24 adults will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35294, United States

Contact

Contact Email: •••••@•••••

Contact

Contact

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER